mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development.
The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, planning and the regulation of therapeutics.
mAbs covers a range of topics, including:
- Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific andtibodies, and single-domain antibodies
- Machine learning and artificial intelligence applications
- Non-clinical studies of antibodies, such as mechanism of action studies, safety and efficacy studies in animals
- Manufacturing and formulation
- Regulatory review of antibody therapeutics
- Post-approval topics, such as markets
mAbs accepts original research papers, brief reports, short communications, reviews, perspectives, commentaries, meeting reports, and article addenda.
The journal operates a single-anonymized peer review policy. All articles will be made freely and permanently available online through gold open access publication.
Read the Instructions for Authors for information on how to submit your article.
*Please note that mAbs converted to a fully Open Access journal beginning with Volume 12 (2020). The 2009-2020 volumes will be free to access from 1 January 2021 .
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})